Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity
and mortality. Steroids remains first line therapy for acute GVHD but there is currently no
consensus on second line therapy for those in whom steroids have been ineffective.
Basiliximab has been shown to be a safe and effective immunosuppresant in the prevention and
treatment of rejection after renal transplantation and its role in acute GVHD prophylaxis and
treatment has been described favourably. This is a randomized control trial to investigate
its efficacy and safety in the management of acute GVHD post allogeneic stem cell
transplantation (SCT).
Phase:
N/A
Details
Lead Sponsor:
Hospital Authority, Hong Kong
Collaborators:
Novartis Pharmaceuticals The Hong Kong Blood Cancer Foundation